Pluristem Granted Key Cell Patents in Asia, Russia, Mexico, and Israel
Company Fortifies IP Assets in Important Markets
HAIFA, Israel, June 1, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. ( PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced it has been granted patents covering cell manufacturing, pharmaceutical compositions and disease treatment in China, South Korea, Mexico, Russia, and Israel.
The State Intellectual Property Office of the People's Republic of China granted Pluristem patent #ZL201080054298.4. It is titled "Adherent Cells from Placenta and Use of Same in Disease Treatment," and addresses the use of adherent placental cells for the treatment of muscle trauma, skeletal muscle defects, neuropathic pain, peripheral nerve injury, and neurodegenerative disease.
The Korean Intellectual Property Office issued to Pluristem patent #KR101490449 titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy." The patent covers important aspects of Pluristem's platform technology, including: adherent placental or adipose cells that were expanded utilizing Pluristem's culture methods; Pluristem's culture methods themselves; and pharmaceutical compositions containing these cells for various therapeutic indications.
Mexico's Instituto Mexicano de la Propiedad Industrial issued to Pluristem patent #MX 327981 titled, "Method and Apparatus for Maintenance and Expansion of Hemopoietic Stem Cells and/or Progenitor Cells," addressing the use of stromal cells for supporting the growth of Hematopoietic Stem Cells in the context of bone marrow transplantation. Pluristem has also been issued patent #MX327763 in Mexico, which is titled "Adherent Cells from Placenta Tissue and Use Thereof in Therapy." This patent addresses methods of growing placental cells under three-dimensional culturing conditions.
The patent titled "Adherent Cells from Placenta Tissue and Use Thereof in Therapy" has also been issued to Pluristem by Rospatent in Russia under patent #RU2539786. This patent addresses adherent placental cells that have been cultured under 3D conditions.
The Israel Patent Office issued the Company patent #IL194232, titled, "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy." The patent addresses methods of growing adherent placental or adipose cells under 3D conditions, cells produced by the methods, methods of producing conditioned medium from the cells, and medium produced by the methods.
"Pluristem has been granted key patents in multiple important markets. We believe the continued expansion of our intellectual property assets fortifies our position as a leader in the development, manufacturing, and clinical application of placental-derived cell therapies," stated Pluristem CEO Zami Aberman. "These newest additions to our IP portfolio are significant as we pursue our strategy to bring PLX cells to markets worldwide." |
